Navigation Links
GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
Date:12/8/2010

ward in our plans for these novel technologies, Phase 2 testing of the NITROSYL systems in patients is an important milestone for GeNO," said GeNO LLC Founder and President David Fine. "As a clinical-stage organization, this trial not only moves the in-hospital solution forward but also enables us to move our other exciting, patent-protected technologies, such as the GeNO Ambulatory NITROSYL System, towards clinical development as well."

Robert F. Roscigno, PhD, Vice President of GeNO, commented, "We believe that this System offers the potential to provide PAH patients, as well as the clinicians that treat them, with a safe and effective diagnostic agent. We look forward to seeing the results of this study, and also to filing additional INDs and completing acute and chronic treatment studies. There is a well-established body of clinical evidence suggesting clinical benefit on the use of inhaled nitric oxide for patients with a variety of serious diseases, and the GeNO NITROSYL Systems would add a valuable option for clinicians treating these difficult conditions.  GeNO's system would help address cost, complexity and the lack of portability of current treatment regimens and potentially reach a much larger group of patients."

The next version of GeNO's platform to enter the clinic later this year will be the GeNO Ambulatory NITROSYL System, which is a hand-held unit with a disposable liquid source.  This portable unit snaps into a small, battery operated pump module attaching to a hip or arm holster and provides up to a 4-day continuous supply of inhaled nitric oxide for chronic use.  The simplicity and ease-of-use this system has the potential to greatly expand the use of inhaled nitric oxide to many new chronic indications.  

ABOUT GeNO LLC

GeNO LLC, founded in 2006, is a privately held, advanced development-stage technology company that is developing innovativ
'/>"/>

SOURCE GeNO LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK
2. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
3. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
4. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
5. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
6. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
7. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
9. Fibrocell Science, Inc. Initiates Histology Study of azficel-T
10. Chimerix Initiates Phase 1 Study of CMX157
11. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Md., July 29, 2014  United Therapeutics Corporation ... its financial results for the second quarter ... growth shows that our medicines are reaching ... arterial hypertension (PAH)," said Martine Rothblatt, Ph.D., ... "The commercial launch this quarter of our ...
(Date:7/29/2014)... San Diego, CA (PRWEB) July 29, 2014 ... added to Pipette.com’s centrifugation product selection. Eppendorf 5427 R ... reverse engineering, and DNA – it is targeted towards ... the Eppendorf Centrifuge 5427 R as it compliments their ... as their Eppendorf line of microcentrifuge tubes, PCR tubes, ...
(Date:7/29/2014)... 2014 White papers by Clinovo ... based eClinical technologies, have been published by leading pharmaceutical ... a long line of white papers by Clinovo to ... Science Leader, Pharmaceutical Online, and OpenHealthNews. , At the ... by CTO Marc Desgrousilliers, 'The Five Essentials of ...
(Date:7/28/2014)... materials using light, developed by researchers at the University ... often considered the realm of science fiction, such as ... starships won,t be a reality for quite some time, ... with building blocks a few billionths of a metre ... light flies through them, and works on large chunks ...
Breaking Biology Technology:United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3Building 'invisible' materials with light 2
... 2012  Avaxia Biologics, Inc., a privately-held biotech company using ... for the treatment of gastrointestinal diseases, announced today that ... Officer of Arisaph Pharmaceuticals, Inc. to its Board of ... has agreed to serve on our Board," said Dr. ...
... Europe,s premier biotech conference continues to grow and see ... network which provides comprehensive support for bioscience businesses in ... announced the results of the sixth annual BioTrinity Biopartnering ... at Newbury Racecourse, UK, BioTrinity is now firmly established ...
... IRVINE, Calif., April 25, 2012 Aviir Diagnostic ... a contractual agreement with MultiPlan, Inc. for ancillary ... in the MultiPlan, PHCS and PHCS Savility Networks. ... cardiologists and scientists from the Stanford University School ...
Cached Biology Technology:Avaxia Biologics Elects Christopher Kiritsy to its Board of Directors 2Another Record Year for BioTrinity 2Another Record Year for BioTrinity 3Aviir Laboratories Announce National Agreement With MultiPlan 2
(Date:7/29/2014)... different types of cell, including sperm, bacteria and ... flagella. These protrusions, about one-hundredth of a millimetre ... through fluid. Similar, shorter structures called cilia are ... they perform roles such as moving liquids over ... remarkably versatile: they transport mucus and expel pathogens ...
(Date:7/28/2014)... 100 drugs already approved by the U.S. Food and ... the growth of certain bacterial pathogens inside human cells, ... spotted fever. The findings, published in mBio , ... Microbiology, demonstrate a new way of identifying non-antibiotic drugs ... , A handful of drugs on the list inhibit ...
(Date:7/28/2014)... Norwegian explorer Roald Amundsen reached the South Pole in ... arrived long before any human. , Using data from ... the Antarctic continent, including the South Pole, a group ... (DRI) in Reno, Nevada, created the most accurate and ... southernmost continent. The new record, described in an article ...
Breaking Biology News(10 mins):Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3New route to identify drugs that can fight bacterial infections 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3
... Oct. 25, 2012 /PRNewswire-iReach/ -- New research shows that ... Maine have demonstrated improvements in health behaviors that persisted ... and rising health care costs continue to challenge employers, ... to reduce health risks and improve health behaviors. ...
... provide the ideal petri dish for cultivating bioscience with ... so, given the opportunity to translate public funding into ... by UCSF researchers. In an analysis published Oct. ... at the California Institute for Quantitative Biosciences (QB3) assessed ...
... Risks of Overfishing," published today in the journal ... the Institute for Ocean Conservation Science and professor at ... According to Dr. Pikitch, current and recent studies demonstrate ... management, in which fishing is restricted to those places ...
Cached Biology News:New Study Shows That Improvements in Employee Health Behaviors Persist Over Two Years 2Academia should fulfill social contract by supporting bioscience startups, case study says 2Academia should fulfill social contract by supporting bioscience startups, case study says 3Traditional fisheries management approach jeopardizes marine ecosystems worldwide 2
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)...
Mouse polyclonal antibody raised against a partial recombinant DDEF2. NCBI Entrez Gene ID = 8853...
Mouse polyclonal antibody to BAG2 - BCL2-associated athanogene 2...
... are multi-functional mixing devices. Stepping motors device ... solid, heavy-duty durable shaker to provide a ... vortexing in nature. Regulated action scale for ... display to control time, continuous time, action ...
Biology Products: